MedPath

Role of Pancreatic Triglyceride Content in Beta-cell Function

Completed
Conditions
Type 2 Diabetes
Obesity
Interventions
Other: No intervention planned.
Registration Number
NCT00602953
Lead Sponsor
University of Texas Southwestern Medical Center
Brief Summary

The study evaluates if fat accumulates in the pancreas in individuals at risk of developing obesity-related diabetes. It also evaluates if the amount of fat in the pancreas can predict the residual functional capacity of the pancreas (insulin secretion).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
101
Inclusion Criteria
  • adults without prior history of pancreatic disease (other than diabetes)
Exclusion Criteria
  • use of unapproved medications
  • contraindications to the MRI procedure
  • contraindications to frequent blood draws
  • pregnancy
  • use of more than 2 alcoholic drinks/day

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Pre-diabetesNo intervention planned.Impaired fasting glucose of impaired glucose tolerance.
OverweightNo intervention planned.Overweight or obese volunteers, but with normal fasting and postprandial glucose levels.
Healthy volunteersNo intervention planned.Normal weight and normal glucose tolerance.
Type 2 diabetesNo intervention planned.Patients with type 2 diabetes.
Type 1 diabetesNo intervention planned.Patients with type 1 diabetes.
Primary Outcome Measures
NameTimeMethod
Pancreatic and Liver FatWithin 1 month after screening visit.

Pancreatic and liver triglyceride (fat) content measured by the magnetic resonance spectroscopy (MRS) technique in volunteers with a wide range of body mass index (BMI).

Beta-cell Function; AIRg - Acute Insulin Response to GlucoseAt screening visit.

Beta-cell function as measured by frequently sampled intravenous glucose tolerance test (FSIVGTT) in volunteers with a wide range of body mass index (BMI).

AIRg - acute insulin response to glucose. Blood samples were collected at -5, -1, 2, 3, 4, 5, 6, 8, 10, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140, and 180 minutes, where time 0 is when an i.v. bolus of 50% glucose solution (0.3 g/kg) was injected.

Insulin Sensitivity (SI)At screening visit.

Sensitivity index measured during frequently sampled intravenous glucose tolerance test (FSIVGTT) in volunteers with a wide range of body mass index (BMI).

Blood samples were collected at -5, -1, 2, 3, 4, 5, 6, 8, 10, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140, and 180 minutes, where time 0 is when an i.v. bolus of 50% glucose solution (0.3 g/kg) was injected. Higher numbers indicates better insulin sensitivity Insulin sensitivity was estimated as Matsuda index using formula = 10,000 / (FPG x FPI x Glucosemean0-180 x Insulinmean0-180)0.5, where FPG = fasting plasma glucose and FPI = fasting plasma insulin.

Disposition Index (DI)At screening visit.

Disposition index measured during frequently sampled intravenous glucose tolerance test (FSIVGTT) in volunteers with a wide range of body mass index (BMI). Blood samples were collected at -5, -1, 2, 3, 4, 5, 6, 8, 10, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140, and 180 minutes, where time 0 is when an i.v. bolus of 50% glucose solution (0.3 g/kg) was injected. Disposition index (DI) was used to characterize the correlation between β-cell sensitivity and insulin sensitivity and was determined using formula DI = AIRg x SI (from outcomes 2 and 3). Higher numbers indicates a better improvement in beta-cell function.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

UT Southwestern Medical Center

🇺🇸

Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath